STAT October 2, 2020
Picture this: As a Covid-19 patient fights for her life on a ventilator, software powered by artificial intelligence analyzes her vital signs and sends her care providers drug-dosing recommendations — even as the same software simultaneously analyzes in real time the vital signs of thousands of other ventilated patients across the country to learn more about how the dosage affects their care and automatically implements improvements to its drug-dosing algorithm.
This type of AI has never been allowed by the Food and Drug Administration. But that day is coming.
AI that continuously learns from new data and modifies itself, called adaptive AI, faces some steep barriers. All FDA-cleared or approved AI-based software is “locked,” meaning the manufacturer cannot allow adaptations...